KFDA approved Il Yang's ilaprazole phase III study

Published: 2005-10-04 06:55:00

Updated: 2005-10-04 06:55:00

Il Yang announced on Sept. 28 that Ilaprozole, an anti-peptic ulcer drug, obtained the KFDA approval on its phase III study for the treatment of duodenal and stomach ulcer, conducting at 15 university hospitals for one year including SNU hospital.

The company said that up to now they spent ab...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK